gms | German Medical Science

57th Annual Meeting of the German Society of Neurosurgery
Joint Meeting with the Japanese Neurosurgical Society

German Society of Neurosurgery (DGNC)

11 - 14 May, Essen

Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours

Expression von Glutathion-S-Transferase T1 (GSTT1) in humanen Hirntumoren

Meeting Abstract

  • corresponding author H.C. Bock - Neurochirurgische Klinik, Georg-August-Universität Göttingen
  • A. Diedrich - Abteilung Histologie, Zentrum Anatomie, Georg-August-Universität Göttingen
  • F. König - Abteilung Neuropathologie, Georg-August-Universität Göttingen
  • H.C. Ludwig - Neurochirurgische Klinik, Georg-August-Universität Göttingen
  • R. Herken - Abteilung Histologie, Zentrum Anatomie, Georg-August-Universität Göttingen
  • F. Quondamatteo - Abteilung Histologie, Zentrum Anatomie, Georg-August-Universität Göttingen

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 57. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie. Essen, 11.-14.05.2006. Düsseldorf, Köln: German Medical Science; 2006. DocP 05.74

The electronic version of this article is the complete one and can be found online at:

Published: May 8, 2006

© 2006 Bock et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Objective: The polymorphic cytosolic enzyme glutathione S-transferase 1 (GSTT1) plays a central role in a number of metabolic processes. Typical substrates for GSTT1 are industrial compounds such as dichloromethane or ethylene oxide. Recently, it has been shown, that also chemotherapeutic drugs such as BCNU [i.e. 1,3-bis(2-chlorethyl)-1-nitroseurea] are efficiently inactivated by GSTT1. Therefore, if GSTT1 would be expressed in neoplastic cells of brain tumours, it might be a factor of chemo resistance.

Methods: Because of its polymorphism we first genotyped the samples for GSTT1 by PCR and used in situ hybridization to show transcript expression of neoplastic cells in both tumour types. A total number of 36 specimen was analyzed. We localized GSTT1 gene expression in malignant gliomas such as glioblastoma multiforme WHO grade IV (6) and oligodendroglioma WHO grade II (2). Control tissues (2) were taken from epilepsy surgery specimen.

Results: High GSTT1 expression could be found in glioblastoma multiforme WHO IV ubiquitiously distributed. Expression was seen in pseudo palisade formations. Mediate expression was localized in oligodendroglioma WHO II. In control tissue gene expression could be shown in larger neurons but was lack in the white matter.

Conclusions: Given the polymorphism of GSTT1 and its potential activity towards chemotherapeutic drugs, its expression in tumours might be considered as a possible factor of non-homogeneous chemotherapy response among patients with different GSTT1 genotypes.